Extending standard target validation approaches, the Compendia Bioscience™ Translational Bioinformatics team can provide clinical relevance for the genomic aberrations seen for your target and nominate applicable model systems to support focused hypothesis-driven experimental testing.

The target survey report provides a complete genomic profile of a target, pathway, or family of genes, with underlying support data. It characterizes amplification, mutation, expression frequency, and differential expression in all major cancer types and subtypes, with integrated analysis across multiple aberration types and recommendations for preclinical model systems.

Hypothesis driven experiments save time and resources

  • Differentiate likely driver from passenger amplifications using focality and frequency of gene amplifications
  • Differentiate hotspot from deleterious mutations using Compendia Bioscience oncogene/tumor suppressor gene algorithms developed by analyzing > 2,500 tumor exomes
  • Gain early indication selection insight from gene expression across >28,000 patient samples
  • Characterize targets enriched in specific tumor types compared to normal tissues
  • Identify targets enriched in patients with poor survival or unmet need for fast-track clinical opportunities
  • Identify cell lines and explants with clinically relevant target aberrations
  • Include your proprietary preclinical models in our analysis to identify models for validation that you already know and accept

Related products

Oncomine concepts edition
rp-ngs-power-tools(230x100)
ryan2(230x100)